X4 Pharmaceuticals, Inc
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
XFOR$3.33+4.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1A.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands, except share amounts)
| Common Stock · AdditionalPaid-InCapital · Accumulated Other ComprehensiveLoss · AccumulatedDeficit · TotalStockholders’Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||||
| Balance at December 31, 2022 | 4,055,575 | $4 | $450,904 | $(119) | $(376,738) | $74,051 | |||||
| Issuance of common stock, warrants and pre-funded warrants for the purchase of common stock, net of issuance costs | 1,150,701 | 1 | 60,442 | 60,443 | |||||||
| Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations | 117,016 | — | — | — | |||||||
| Exercise of stock options and warrants | 249,261 | 1 | 8,812 | 8,813 | |||||||
| Stock-based compensation expense | 8,687 | 8,687 | |||||||||
| Issuance of shares of common stock under employee stock purchase plan | 8,600 | 272 | 272 | ||||||||
| Net loss | (101,167) | (101,167) | |||||||||
| Balance at December 31, 2023 | 5,581,153 | $6 | $529,117 | $(119) | $(477,905) | $51,099 | |||||
| Issuance of common stock under employee stock purchase plan | 21,185 | — | 297 | 297 | |||||||
| Vesting of restricted stock units | 95,893 | — | 2 | 2 | |||||||
| Stock-based compensation | 8,204 | 8,204 | |||||||||
| Unrealized loss on marketable securities | (3) | (3) | |||||||||
| Net loss | (37,450) | (37,450) | |||||||||
| Balance at December 31, 2024 | 5,698,231 | $6 | $537,620 | $(122) | $(515,355) | $22,149 | |||||
| Issuance of common stock and pre-funded warrants for the purchase of common stock, net of issuance costs | 69,688,750 | 70 | 238,855 | 238,925 | |||||||
| Exercise of pre-funded warrants | 15,241,246 | 15 | — | 15 | |||||||
| Issuance of common stock under employee stock purchase plan | 38,769 | — | 89 | 89 | |||||||
| Vesting of restricted stock units | 239,924 | — | — | — | |||||||
| Stock-based compensation | 4,298 | 4,298 | |||||||||
| Unrealized losses on marketable securities | 13 | 13 | |||||||||
| Net loss | (79,199) | (79,199) | |||||||||
| Balance at December 31, 2025 | 90,906,920 | $91 | $780,862 | $(109) | $(594,554) | $186,290 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.